Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeurogesX has initiated dosing in its Phase I clinical trial of NGX-1998. The product candidate is a high-concentration, capsaicin-based liquid formulation designed to deliver a localized therapeutic dose directly to the pain site.
Subscribe to our email newsletter
The randomized, single-blind Phase I trial is designed to evaluate potential control formulations for future NGX-1998 clinical trials. NeurogesX expects to complete the trial by the end of 2008.
The objective of the NGX-1998 development program is to determine the ability of NGX-1998 to provide protracted pain relief from a single treatment.
Anthony DiTonno, president and CEO of NeurogesX, said: “The initiation of this Phase I trial of NGX-1998 marks a significant step in our program to develop a second-generation liquid formulation of capsaicin to manage pain. We believe that our Phase I trial will provide us with important information that will help shape the design of further studies with the product candidate.”